Temporal Interference Noninvasive Deep Brain Stimulation for Idiopathic Parkinson's Disease and Parkinsonian Syndromes: Effects and Target Exploration
10. Juli 2026 aktualisiert von: Shengdi Chen, Ruijin Hospital
A Study on the Therapeutic Effects and Target Exploration of Temporal Interference-Based Noninvasive Deep Brain Stimulation in Patients With Idiopathic Parkinson's Disease and Parkinsonian Syndromes
This study aims to explore the therapeutic effects of noninvasive deep brain electrical stimulation using temporal interference principles (Temporal Interference Stimulation, TIS) on both motor and non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes, and to investigate strategies for optimal stimulation target selection. A prospective, single-center, double-blind, randomized, crossover design will be implemented. Participants will be recruited from outpatient and inpatient departments of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The primary hypothesis is that TIS will significantly improve motor symptoms in patients with Parkinson's disease and Parkinsonian syndromes. The primary outcome measure will be the change in the MDS-UPDRS Part III score from baseline to post-stimulation.
This study is expected to provide direct evidence supporting the clinical application and target selection strategies of noninvasive deep brain stimulation for the treatment of Parkinson's disease and Parkinsonian syndromes.
Studienübersicht
Status
Anmeldung auf Einladung
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Geschätzt)
100
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Shanghai, China
- Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Beschreibung
Inclusion Criteria:
- Aged 40 to 80 years, diagnosed with idiopathic Parkinson's disease or Parkinsonian syndromes according to the Movement Disorder Society (MDS) diagnostic criteria.
- Receiving stable doses of levodopa or other dopaminergic medications for at least 4 weeks prior to enrollment, with a documented response to levodopa; medication regimen must remain unchanged during the study.
- Hoehn and Yahr (H&Y) stage ≤ 3 in the "ON" medication state.
- Normal cognitive function, defined as a Mini-Mental State Examination (MMSE) score ≥ 24.
- Able to maintain and cooperate with Parkinson's disease symptom diaries.
- Signed written informed consent.
Exclusion Criteria:
- Presence of other neurological or psychiatric disorders that may interfere with study participation or outcomes.
- Previous treatment with deep brain stimulation (DBS) or other invasive brain stimulation therapies.
- Orthopedic or other medical conditions that could affect gait or balance.
- Contraindications to MRI, such as claustrophobia or other factors making MRI unsuitable.
- History of taking antipsychotic, antidepressant, or other medications that may affect dopamine levels.
- Contraindications to electrical stimulation, such as implanted cardiac pacemakers or a history of epilepsy.
- History of electroconvulsive therapy (ECT).
- Severe comorbidities, including cardiovascular disease, respiratory disease, or hepatic/renal dysfunction.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: GPi TIS
Participants with PD or PDS receive TIS targeting the contralateral globus pallidus internus (GPi).
Each group consists of 10 patients with PD and 10 patients with PDS.
|
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with AB sequence (Active → Sham).
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with BA sequence (Sham → Active).
Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
|
|
Experimental: STN TIS
Participants with PD or PDS receive TIS targeting the contralateral subthalamic nucleus (STN).
Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
|
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with AB sequence (Active → Sham).
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with BA sequence (Sham → Active).
Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
|
|
Experimental: Putamen TIS
Participants with PD or PDS receive TIS targeting the contralateral putamen.
Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
|
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with AB sequence (Active → Sham).
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with BA sequence (Sham → Active).
Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
|
|
Experimental: LHA TIS
Participants with PD or PDS receive TIS targeting the contralateral lateral hypothalamic area (LHA).
Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
|
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with AB sequence (Active → Sham).
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with BA sequence (Sham → Active).
Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
|
|
Experimental: Dentate TIS
Participants with PD or PDS receive TIS targeting the ipsilateral cerebellar dentate nucleus.
Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
|
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with AB sequence (Active → Sham).
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS.
Each session lasts 30 minutes for 3 consecutive days.
The study uses a crossover design with BA sequence (Sham → Active).
Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Efficacy of temporal interference stimulation (TIS) on motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The MDS-UPDRS Part III is a rater-administered motor examination used to evaluate the severity of motor impairment in patients with idiopathic Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 132, with lower scores indicating less severe motor symptoms.
Changes from baseline after real or sham stimulation will be analyzed and compared between groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Secondary motor outcome
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The UMSARS is a rater-administered scale used to assess disease severity in patients with Parkinsonian syndromes, particularly multiple system atrophy.
The total score ranges from 0 to 104, with a higher score indicating greater disease severity.
The change in UMSARS score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Secondary motor outcome
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Freezing of Gait Questionnaire is used to assess the severity and frequency of freezing of gait in patients with idiopathic Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 24, with a higher score indicating more severe freezing of gait.
The change in FOGQ score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Secondary motor outcome
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Berg Balance Scale is a rater-administered scale used to assess balance function and fall risk.
The total score ranges from 0 to 56, with a higher score indicating better balance function.
The change in Berg Balance Scale score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Hamilton Anxiety Rating Scale-14（HAMA-14）is a rater-administered scale used to assess the severity of anxiety symptoms.
The total score ranges from 0 to 56, with a higher score indicating more severe anxiety.
The change in HAMA-14 score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Hamilton Depression Rating Scale-17（HAMD-17）is a rater-administered scale used to assess the severity of depressive symptoms.
The total score ranges from 0 to 52, with a higher score indicating more severe depression.
The change in HAMD-17 score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Mini-Mental State Examination（MMSE）is a brief cognitive screening scale used to assess global cognitive function.
The total score ranges from 0 to 30, with a higher score indicating better cognitive function.
The change in MMSE score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Montreal Cognitive Assessment（MoCA）is a brief cognitive screening scale used to assess global cognitive function, particularly mild cognitive impairment.
The total score ranges from 0 to 30, with a higher score indicating better cognitive function.
The change in MoCA score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Non-Motor Symptoms Scale（NMSS）is a rater-administered scale used to assess the severity and frequency of non-motor symptoms in patients with Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 360, with a higher score indicating a greater non-motor symptom burden.
The change in NMSS score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Scales for Outcomes in Parkinson's Disease-Autonomic Dysfunction（SCOPA-AUT）is a patient-reported scale used to assess autonomic symptoms in patients with Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 69, with a higher score indicating more severe autonomic dysfunction.
The change in SCOPA-AUT score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on quality of life in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The Parkinson's Disease Questionnaire-39 Summary Index（PDQ-39 SI）is a patient-reported scale used to assess health-related quality of life in patients with Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 100, with a higher score indicating poorer quality of life.
The change in PDQ-39 SI score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on quality of life in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The MDS-UPDRS Part I is used to assess non-motor experiences of daily living in patients with idiopathic Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 52, with a higher score indicating more severe non-motor symptom burden.
The change in MDS-UPDRS Part I score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Efficacy of TIS on quality of life in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
The MDS-UPDRS Part II is used to assess motor experiences of daily living in patients with idiopathic Parkinson's disease and Parkinsonian syndromes.
The total score ranges from 0 to 52, with a higher score indicating greater motor-related impairment in daily living.
The change in MDS-UPDRS Part II score from baseline to after stimulation will be compared between the real and sham stimulation groups.
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Potential mechanisms underlying the therapeutic effects of TIS in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
Changes in resting-state EEG β-band oscillation power before and after stimulation
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Potential mechanisms underlying the therapeutic effects of TIS in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Zeitfenster: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
Changes in whole-brain resting-state fMRI functional connectivity strength, with exploratory analyses focusing on the sensorimotor and basal ganglia networks, before and after stimulation
|
Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
|
|
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: From baseline through study completion (up to 3 weeks)
|
The number and severity of all AEs and SAEs will be collected and monitored throughout the study to evaluate the safety and tolerability of the intervention.
|
From baseline through study completion (up to 3 weeks)
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
3. Juli 2026
Primärer Abschluss (Geschätzt)
30. September 2026
Studienabschluss (Geschätzt)
30. September 2026
Studienanmeldedaten
Zuerst eingereicht
8. Dezember 2025
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
10. Juli 2026
Zuerst gepostet (Tatsächlich)
13. Juli 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
13. Juli 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
10. Juli 2026
Zuletzt verifiziert
1. Juli 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2025-622
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur AB Temporal Interference Stimulation
-
Medical University of ViennaAbgeschlossenMuskelabbau | Erworbene Schwäche auf der Intensivstation | Neuromuskuläre Elektrostimulation | Kraftverschwendung